EP1567863A4 - Therapie- und diagnoseverfahren - Google Patents

Therapie- und diagnoseverfahren

Info

Publication number
EP1567863A4
EP1567863A4 EP03786850A EP03786850A EP1567863A4 EP 1567863 A4 EP1567863 A4 EP 1567863A4 EP 03786850 A EP03786850 A EP 03786850A EP 03786850 A EP03786850 A EP 03786850A EP 1567863 A4 EP1567863 A4 EP 1567863A4
Authority
EP
European Patent Office
Prior art keywords
diagnosis
therapy
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03786850A
Other languages
English (en)
French (fr)
Other versions
EP1567863A2 (de
Inventor
Douglas Dedera
Peter C R Emtage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvelo Inc
Original Assignee
Nuvelo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/302,444 external-priority patent/US20040022786A1/en
Priority claimed from US10/327,491 external-priority patent/US20040023870A1/en
Application filed by Nuvelo Inc filed Critical Nuvelo Inc
Publication of EP1567863A2 publication Critical patent/EP1567863A2/de
Publication of EP1567863A4 publication Critical patent/EP1567863A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP03786850A 2002-11-22 2003-11-19 Therapie- und diagnoseverfahren Withdrawn EP1567863A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/302,444 US20040022786A1 (en) 2000-01-21 2002-11-22 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US302444 2002-11-22
US10/327,491 US20040023870A1 (en) 2000-01-21 2002-12-19 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
US327491 2002-12-19
US64122203A 2003-08-13 2003-08-13
US641222 2003-08-13
PCT/US2003/036971 WO2004047612A2 (en) 2002-11-22 2003-11-19 Methods of therapy and diagnosis

Publications (2)

Publication Number Publication Date
EP1567863A2 EP1567863A2 (de) 2005-08-31
EP1567863A4 true EP1567863A4 (de) 2007-10-03

Family

ID=32397926

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03786850A Withdrawn EP1567863A4 (de) 2002-11-22 2003-11-19 Therapie- und diagnoseverfahren

Country Status (4)

Country Link
EP (1) EP1567863A4 (de)
AU (1) AU2003295649A1 (de)
CA (1) CA2506356A1 (de)
WO (1) WO2004047612A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005477A1 (en) 2004-07-09 2006-01-19 Schering Ag Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma
MX2007000770A (es) * 2004-07-20 2007-03-26 Schering Corp Induccion de apoptosis en celulas tumorales que expresan el receptor tipo toll.
CN120131958B (zh) * 2025-03-12 2026-04-07 广东药科大学 Tlr1受体抑制剂在制备治疗高血压产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020756A2 (en) * 1997-10-17 1999-04-29 Genentech, Inc. Human toll homologues

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020756A2 (en) * 1997-10-17 1999-04-29 Genentech, Inc. Human toll homologues

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOURKE E ET AL: "THE TOLL-LIKE RECEPTOR REPERTOIRE OF HUMAN B LYMPHOCYTES:INDUCIBLE AND SELECTIVE EXPRESSION OF TLR9 AND TLR10 IN NORMAL AND TRANSFORMED CELLS", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 102, no. 3, 1 August 2003 (2003-08-01), pages 956 - 963, XP002997453, ISSN: 0006-4971 *
CHAFFOIS CLAIRE ET AL: "Toll-like receptor 10 is expressed by human B cells and plasmacytoid DC, and has no functional equivalent in mouse.", EUROPEAN CYTOKINE NETWORK, vol. 14, no. Supplement 3, September 2003 (2003-09-01), & ANNUAL MEETING OF THE INTERNATIONAL CYTOKINE SOCIETY; DUBLIN, IRELAND; SEPTEMBER 20-24, 2003, pages 118, XP009088554, ISSN: 1148-5493 *
CHUANG T-H ET AL: "Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells", BIOCHIMICA ET BIOPHYSICA ACTA . GENE STRUCTURE AND EXPRESSION, ELSEVIER, AMSTERDAM, NL, vol. 1518, no. 1-2, 19 March 2001 (2001-03-19), pages 157 - 161, XP004275868, ISSN: 0167-4781 *
HORNUNG VEIT ET AL: "Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 168, no. 9, 1 May 2002 (2002-05-01), pages 4531 - 4537, XP002438973, ISSN: 0022-1767 *
NAGASE HIROYUKI ET AL: "Expression and function of toll-like receptors in eosinophils: Activation by Toll-like receptor 7 ligand.", JOURNAL OF IMMUNOLOGY, vol. 171, no. 8, 15 October 2003 (2003-10-15), pages 3977 - 3982, XP002447891, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
CA2506356A1 (en) 2004-06-10
WO2004047612A2 (en) 2004-06-10
AU2003295649A1 (en) 2004-06-18
WO2004047612A3 (en) 2005-04-14
EP1567863A2 (de) 2005-08-31

Similar Documents

Publication Publication Date Title
EP1578380A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von prostatakrebs
EP1390077A4 (de) Behandlung und diagnose vom makrophagen-vermittelter erkrankung
AU2003261073A8 (en) Combined diagnostic and therapeutic ultrasound system
NO20043359L (no) Anordning for ikke-invasiv ultralydbehandling av et objekt
EP1600099A4 (de) Sammelvorrichtung für kapselartige medizinische einheit und sammelverfahren
NO20003853D0 (no) Forbindelser for terapi og diagnose av lungekreft og metoder for deres anvendelse
FI20021532A0 (fi) Lääketieteellinen röntgenkuvausmenetelmä ja -järjestely
IL162201A0 (en) New methods for diagnosis and treatment of tumours
EP1516049A4 (de) Zusammensetzungen und verfahren für die therapie und diagnose von lungenkrebs
NO20024972D0 (no) Blandinger og fremgangsmåter for terapi og diagnose av brystkreft
EP1539251A4 (de) Zusammensetzungen und verfahren zur diagnose und therapie von medizinischen erkrankungen mit angiogenese
EP1446013A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
EP1573440A4 (de) Verfahren zur diagnose von akathisie
EP1608967A4 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
EP1552019A4 (de) Krebsdiagnostik und -prognose
EP1781685A4 (de) Therapeutische und diagnostische mittel
EP1575993A4 (de) Verfahren zur behandlung von patienten und zur identifizierung von therapeutika
EP1546714A4 (de) Zusammensetzungen und verfahren zur verwendung beim abzielen auf peptide zur diagnose und therapie von krebs im menschen
EP1589980A4 (de) Verfahren zur diagnose und behandlung voninterstitieller lungenerkrankung
FI20021617A0 (fi) Diagnostisia ja terapeuttisia menetelmiä
EP1496743A4 (de) Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs
EP1495717A4 (de) Verfahren zur diagnose des menschlichen organismus
AU2003223033A8 (en) System for point of care diagnosis and/or analysis
EP1567863A4 (de) Therapie- und diagnoseverfahren
AU2003278497A8 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050617

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20070905

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALN20070827BHEP

Ipc: A61K 39/395 20060101ALI20070827BHEP

Ipc: G01N 33/53 20060101AFI20050425BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071205